SOLVO Biotechnology | A Charles River Compan

solvo.com

With 17 years of experience and 500 customers in 40 countries, SOLVO Biotechnology is the leading provider of transporter services and products. Leveraging our expertise in efflux and uptake transporters, SOLVO generates quality reports for submission to FDA/EMA. From small molecules to protein therapeutics, SOLVO can test all your transporter needs.

C-Suite On Deck

Responsive image

Feature market insights and perspectives from top C-Level executives, elite technology influencers and thought leaders from your company here. This signature initiative has garnered immense support...

Contact Us

Events

Related News

Cell and Gene Therapy, Industrial Impact

EXELIXIS AND SAIROPA ANNOUNCE FDA CLEARANCE OF IND APPLICATION

Exelixis | February 14, 2023

news image

On February 13, 2023, Exelixis, Inc., a leading global oncology firm innovating next-generation medicines and regimens at the forefront of cancer care and Sairopa B.V. (Sairopa), a renowned firm developing novel therapeutics for cancer by modulating the patient's immune system, announced that FDA has approved Sairopa's Investigational New Drug (IND) Application to assess the pharmacokinetics and safety of ADU-1805 in adults with advanced solid tumors. ADU-1805, being a m...

Read More

Industrial Impact

CALYXT ANNOUNCES PRICING OF OFFERING OF COMMON STOCK AND WARRANTS AND UPDATES BUSINESS AND RISK FACTOR DISCLOSURE

Cellectis Inc. | February 19, 2022

news image

Cellectis, a clinical-stage biotechnology company using its pioneering gene-editing platform to develop life-saving cell and gene therapies, and Calyxt, Inc. , a majority-owned subsidiary of Cellectis S.A., announced the placement to an institutional investor in an underwritten offering of (i) 3,880,000 shares of Calyxt common stock, (ii) pre-funded warrants to purchase up to 3,880,000 shares of its common stock, and (iii) common warrants to purchase up to 7,760,000 shares of its common stock. Read More

Cell and Gene Therapy

SESEN BIO AND CARISMA THERAPEUTICS ANNOUNCE MERGER AGREEMENT

Sesen Bio and Carisma Therapeutics | September 22, 2022

news image

Sesen Bio, Inc. and Carisma Therapeutics Inc. a privately held, clinical stage biopharmaceutical company focused on discovering and developing innovative immunotherapies, announced that they have entered into a definitive merger agreement to combine the companies in an all-stock transaction. The combined company will focus on the advancement of Carisma’s proprietary cell therapy platform that utilizes engineered macrophages and monocytes to potentially transform the treatment of cancer and...

Read More

AI

LABCORP AND PATHAI EXPAND THEIR PARTNERSHIP TO ACCELERATE USE OF AI-POWERED PATHOLOGY

PathAI, Labcorp | March 09, 2021

news image

PathAI, a global supplier of artificial intelligence-powered (AI-powered) innovation for use in pathology research, and Labcorp, a main global life sciences company, today declared the expanding of their essential organization in the field of AI-powered pathology. The coordinated effort expands on Labcorp's past investment in PathAI and the companies' cooperation on a progression of projects, remembering the deployment of PathAI algorithms for clinical trials oversaw by Labcorp Drug Deve...

Read More
news image

Cell and Gene Therapy, Industrial Impact

EXELIXIS AND SAIROPA ANNOUNCE FDA CLEARANCE OF IND APPLICATION

Exelixis | February 14, 2023

On February 13, 2023, Exelixis, Inc., a leading global oncology firm innovating next-generation medicines and regimens at the forefront of cancer care and Sairopa B.V. (Sairopa), a renowned firm developing novel therapeutics for cancer by modulating the patient's immune system, announced that FDA has approved Sairopa's Investigational New Drug (IND) Application to assess the pharmacokinetics and safety of ADU-1805 in adults with advanced solid tumors. ADU-1805, being a m...

Read More
news image

Industrial Impact

CALYXT ANNOUNCES PRICING OF OFFERING OF COMMON STOCK AND WARRANTS AND UPDATES BUSINESS AND RISK FACTOR DISCLOSURE

Cellectis Inc. | February 19, 2022

Cellectis, a clinical-stage biotechnology company using its pioneering gene-editing platform to develop life-saving cell and gene therapies, and Calyxt, Inc. , a majority-owned subsidiary of Cellectis S.A., announced the placement to an institutional investor in an underwritten offering of (i) 3,880,000 shares of Calyxt common stock, (ii) pre-funded warrants to purchase up to 3,880,000 shares of its common stock, and (iii) common warrants to purchase up to 7,760,000 shares of its common stock. Read More

news image

Cell and Gene Therapy

SESEN BIO AND CARISMA THERAPEUTICS ANNOUNCE MERGER AGREEMENT

Sesen Bio and Carisma Therapeutics | September 22, 2022

Sesen Bio, Inc. and Carisma Therapeutics Inc. a privately held, clinical stage biopharmaceutical company focused on discovering and developing innovative immunotherapies, announced that they have entered into a definitive merger agreement to combine the companies in an all-stock transaction. The combined company will focus on the advancement of Carisma’s proprietary cell therapy platform that utilizes engineered macrophages and monocytes to potentially transform the treatment of cancer and...

Read More
news image

AI

LABCORP AND PATHAI EXPAND THEIR PARTNERSHIP TO ACCELERATE USE OF AI-POWERED PATHOLOGY

PathAI, Labcorp | March 09, 2021

PathAI, a global supplier of artificial intelligence-powered (AI-powered) innovation for use in pathology research, and Labcorp, a main global life sciences company, today declared the expanding of their essential organization in the field of AI-powered pathology. The coordinated effort expands on Labcorp's past investment in PathAI and the companies' cooperation on a progression of projects, remembering the deployment of PathAI algorithms for clinical trials oversaw by Labcorp Drug Deve...

Read More